Page Header

Sidebar
WHO Optimal Formulary
Dolutegravir (DTG)
  • Form
    Tablet
  • Strength
    50mg
  • Indication
    Preferred First-line & Second-Line Treatment
Abacavir (ABC)/Lamivudine (3TC)
  • Form
    Tablet
  • Strength
    120 mg/60 mg
  • Indication
    Preferred First-line & Second-Line Treatment
Raltergravir(RAL)
  • Form
    Chewable Tablet
  • Strength
    25mg
  • Indication
    Alternative First-line & Second-Line Treatment
Lopinavir/ritonavir(LPV/r)
  • Form
    Tablet
  • Strength
    100 mg/25 mg
  • Indication
    Alternative First-line & Second-Line Treatment
Lopinavir/ritonavir(LPV/r)
  • Form
    Oral Pellets
  • Strength
    40 mg/10 mg
  • Indication
    Alternative First-line & Second-Line Treatment
Zidovudine (AZT)/ Lamivudine(3TC)
  • Form
    Dispersible Tablet
  • Strength
    AZT/3TC Tablet 60mg/30mg
  • Indication
    First-line in Special Circumstances or Second-Line in Infants and Children 4-25 kg
Zidovudine (AZT)
  • Form
    Oral Solution
  • Strength
    50 mg/5mL
  • Indication
    For Postnatal Prophylaxis or Neonatal Treatment ONLY
Nevirapine (NVP)
  • Form
    Tablet
  • Strength
    50mg
  • Indication
    For Postnatal Prophylaxis or Neonatal Treatment ONLY
Nevirapine (NVP)
  • Form
    Oral Solution
  • Strength
    50 mg/5mL
  • Indication
    For Postnatal Prophylaxis or Neonatal Treatment ONLY